<DOC>
	<DOC>NCT03003416</DOC>
	<brief_summary>This study will evaluate the efficacy of Ozurdex® as prescribed in clinical practice in France for the treatment of Diabetic Macular Edema (DME).</brief_summary>
	<brief_title>Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient with Diabetic Macular Edema (DME) treated with Ozurdex® in clinical practice. Patient not residing in metropolitan France.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>